Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	extracellular matrix structural constituent	COL9A2 VWF PXDN LAMA4 SRPX MUC2 SSPOP MUC5AC	1.16e-07	188	62	8	GO:0005201
GeneOntologyMolecularFunction	H3K27me3 modified histone binding	TAF1 TAF1L	9.43e-05	5	62	2	GO:0061628
GeneOntologyMolecularFunction	complement binding	CR2 MASP2 CFHR4	1.33e-04	32	62	3	GO:0001848
GeneOntologyMolecularFunction	RNA polymerase I general transcription initiation factor activity	TAF1 TAF1L	3.37e-04	9	62	2	GO:0001181
GeneOntologyMolecularFunction	structural molecule activity	COL9A2 VWF PXDN SPRR3 LAMA4 SRPX ERVK-24 MUC2 SSPOP MUC5AC	3.88e-04	891	62	10	GO:0005198
GeneOntologyMolecularFunction	dipeptidyl-peptidase activity	DPP9 DPP8	6.14e-04	12	62	2	GO:0008239
GeneOntologyMolecularFunction	high voltage-gated calcium channel activity	CACNA1C CACNA1I	8.43e-04	14	62	2	GO:0008331
GeneOntologyBiologicalProcess	cell-matrix adhesion	ADAMTS12 PTPN11 PTPRK ADAM15 ADAMTS13 ZYX SVEP1	1.62e-05	270	62	7	GO:0007160
GeneOntologyBiologicalProcess	cell-substrate adhesion	ADAMTS12 PTPN11 VWF PTPRK ADAM15 ADAMTS13 ZYX SVEP1	3.01e-05	410	62	8	GO:0031589
GeneOntologyBiologicalProcess	complement activation	CR2 SVEP1 MASP2 CFHR4	5.85e-05	70	62	4	GO:0006956
GeneOntologyBiologicalProcess	regulation of complement activation	CR2 SVEP1 CFHR4	7.19e-05	27	62	3	GO:0030449
GeneOntologyCellularComponent	extracellular matrix	ADAMTS12 SSC5D COL9A2 VWF PXDN LAMA4 ADAMTS13 SRPX GDF10 MUC2 SSPOP MUC5AC SVEP1	6.29e-08	656	63	13	GO:0031012
GeneOntologyCellularComponent	external encapsulating structure	ADAMTS12 SSC5D COL9A2 VWF PXDN LAMA4 ADAMTS13 SRPX GDF10 MUC2 SSPOP MUC5AC SVEP1	6.51e-08	658	63	13	GO:0030312
GeneOntologyCellularComponent	mucus layer	MUC2 MUC5AC	2.68e-05	3	63	2	GO:0070701
GeneOntologyCellularComponent	collagen-containing extracellular matrix	SSC5D COL9A2 VWF PXDN LAMA4 SRPX GDF10 MUC2 SSPOP	2.83e-05	530	63	9	GO:0062023
Domain	Unchr_dom_Cys-rich	VWF KCP MUC2 SSPOP MUC5AC	3.64e-10	13	60	5	IPR014853
Domain	C8	VWF KCP MUC2 SSPOP MUC5AC	3.64e-10	13	60	5	SM00832
Domain	TIL_dom	VWF KCP MUC2 SSPOP MUC5AC	5.65e-10	14	60	5	IPR002919
Domain	VWD	VWF KCP MUC2 SSPOP MUC5AC	1.23e-09	16	60	5	SM00216
Domain	VWF_type-D	VWF KCP MUC2 SSPOP MUC5AC	1.23e-09	16	60	5	IPR001846
Domain	VWFD	VWF KCP MUC2 SSPOP MUC5AC	1.23e-09	16	60	5	PS51233
Domain	VWD	VWF KCP MUC2 SSPOP MUC5AC	1.23e-09	16	60	5	PF00094
Domain	VWFC_1	VWF PXDN KCP MUC2 SSPOP MUC5AC	1.54e-09	36	60	6	PS01208
Domain	VWC	VWF PXDN KCP MUC2 SSPOP MUC5AC	2.17e-09	38	60	6	SM00214
Domain	VWFC_2	VWF PXDN KCP MUC2 SSPOP MUC5AC	2.17e-09	38	60	6	PS50184
Domain	VWC_out	VWF KCP MUC2 SSPOP MUC5AC	3.24e-09	19	60	5	SM00215
Domain	VWF_dom	VWF PXDN KCP MUC2 SSPOP MUC5AC	4.08e-09	42	60	6	IPR001007
Domain	Sushi	SRPX CR2 SEZ6L2 SVEP1 MASP2 CFHR4	1.54e-08	52	60	6	PF00084
Domain	CCP	SRPX CR2 SEZ6L2 SVEP1 MASP2 CFHR4	1.95e-08	54	60	6	SM00032
Domain	SUSHI	SRPX CR2 SEZ6L2 SVEP1 MASP2 CFHR4	2.44e-08	56	60	6	PS50923
Domain	Sushi_SCR_CCP_dom	SRPX CR2 SEZ6L2 SVEP1 MASP2 CFHR4	2.72e-08	57	60	6	IPR000436
Domain	TIL	VWF MUC2 SSPOP MUC5AC	4.67e-08	12	60	4	PF01826
Domain	C8	VWF MUC2 SSPOP MUC5AC	4.67e-08	12	60	4	PF08742
Domain	CTCK_1	VWF MUC2 SSPOP MUC5AC	2.85e-07	18	60	4	PS01185
Domain	Cys_knot_C	VWF MUC2 SSPOP MUC5AC	1.16e-06	25	60	4	IPR006207
Domain	CTCK_2	VWF MUC2 SSPOP MUC5AC	1.16e-06	25	60	4	PS01225
Domain	VWC	VWF PXDN KCP MUC5AC	1.86e-06	28	60	4	PF00093
Domain	TAF_II_230-bd	TAF1 TAF1L	1.01e-05	2	60	2	IPR009067
Domain	TFIID_sub1_DUF3591	TAF1 TAF1L	1.01e-05	2	60	2	IPR022591
Domain	-	TAF1 TAF1L	1.01e-05	2	60	2	1.10.1100.10
Domain	BMP3/BMP3B	BMP3 GDF10	1.01e-05	2	60	2	IPR017197
Domain	TBP-binding	TAF1 TAF1L	1.01e-05	2	60	2	PF09247
Domain	DUF3591	TAF1 TAF1L	1.01e-05	2	60	2	PF12157
Domain	TAF1_animal	TAF1 TAF1L	1.01e-05	2	60	2	IPR011177
Domain	HYR	SRPX SVEP1	3.04e-05	3	60	2	PS50825
Domain	HYR	SRPX SVEP1	3.04e-05	3	60	2	PF02494
Domain	HYR_dom	SRPX SVEP1	3.04e-05	3	60	2	IPR003410
Domain	CT	VWF MUC2 MUC5AC	4.65e-05	22	60	3	SM00041
Domain	TSP_1	ADAMTS12 THSD7A ADAMTS13 SSPOP	4.97e-05	63	60	4	PF00090
Domain	TSP1	ADAMTS12 THSD7A ADAMTS13 SSPOP	5.63e-05	65	60	4	SM00209
Domain	TSP1_rpt	ADAMTS12 THSD7A ADAMTS13 SSPOP	5.63e-05	65	60	4	IPR000884
Domain	TSP1	ADAMTS12 THSD7A ADAMTS13 SSPOP	5.63e-05	65	60	4	PS50092
Domain	-	DPP9 DPP8	1.51e-04	6	60	2	2.140.10.30
Domain	DPPIV_N	DPP9 DPP8	1.51e-04	6	60	2	PF00930
Domain	WxxW_domain	MUC2 MUC5AC	1.51e-04	6	60	2	IPR025155
Domain	Mucin2_WxxW	MUC2 MUC5AC	1.51e-04	6	60	2	PF13330
Domain	Peptidase_S9B_N	DPP9 DPP8	1.51e-04	6	60	2	IPR002469
Domain	DISINTEGRIN_1	ADAMTS12 ADAM15 ADAMTS13	2.86e-04	40	60	3	PS00427
Domain	Reprolysin	ADAMTS12 ADAM15 ADAMTS13	2.86e-04	40	60	3	PF01421
Domain	ADAM_MEPRO	ADAMTS12 ADAM15 ADAMTS13	2.86e-04	40	60	3	PS50215
Domain	DISINTEGRIN_2	ADAMTS12 ADAM15 ADAMTS13	2.86e-04	40	60	3	PS50214
Domain	Peptidase_M12B	ADAMTS12 ADAM15 ADAMTS13	2.86e-04	40	60	3	IPR001590
Domain	Disintegrin_dom	ADAMTS12 ADAM15 ADAMTS13	3.08e-04	41	60	3	IPR001762
Domain	Pept_M10_metallopeptidase	ADAMTS12 ADAM15 ADAMTS13	3.55e-04	43	60	3	IPR001818
Domain	VDCCAlpha1	CACNA1C CACNA1I	4.49e-04	10	60	2	IPR002077
Domain	Peptidase_S9	DPP9 DPP8	5.48e-04	11	60	2	PF00326
Domain	Peptidase_S9	DPP9 DPP8	5.48e-04	11	60	2	IPR001375
Domain	CUB	ADAMTS13 SEZ6L2 MASP2	6.59e-04	53	60	3	PS01180
Domain	CUB_dom	ADAMTS13 SEZ6L2 MASP2	8.15e-04	57	60	3	IPR000859
Domain	EGF_1	ADAM15 LAMA4 SSPOP SVEP1 MASP2	1.35e-03	255	60	5	PS00022
Domain	MetalloPept_cat_dom	ADAMTS12 ADAM15 ADAMTS13	2.25e-03	81	60	3	IPR024079
Domain	-	ADAMTS12 ADAM15 ADAMTS13	2.25e-03	81	60	3	3.40.390.10
Domain	Peptidase_M12B_ADAM-TS	ADAMTS12 ADAMTS13	2.68e-03	24	60	2	IPR013273
Domain	Ephrin_rec_like	TNFRSF21 SVEP1	2.90e-03	25	60	2	SM01411
Domain	Tyr-kin_ephrin_A/B_rcpt-like	TNFRSF21 SVEP1	2.90e-03	25	60	2	IPR011641
Domain	Bromodomain_CS	TAF1 TAF1L	3.14e-03	26	60	2	IPR018359
Domain	ACR	ADAM15 ADAMTS13	3.38e-03	27	60	2	SM00608
Domain	ADAM_Cys-rich	ADAM15 ADAMTS13	3.38e-03	27	60	2	IPR006586
Domain	TGFb_propeptide	BMP3 GDF10	3.64e-03	28	60	2	PF00688
Domain	TGF-b_N	BMP3 GDF10	3.64e-03	28	60	2	IPR001111
Domain	ZINC_PROTEASE	ADAMTS12 ADAM15 ADAMTS13	3.86e-03	98	60	3	PS00142
Domain	TGF-beta-rel	BMP3 GDF10	4.73e-03	32	60	2	IPR015615
Domain	TGFb_CS	BMP3 GDF10	4.73e-03	32	60	2	IPR017948
Domain	PTPc	PTPN11 PTPRK	5.96e-03	36	60	2	SM00194
Domain	TGFB	BMP3 GDF10	6.29e-03	37	60	2	SM00204
Domain	TGF-b_C	BMP3 GDF10	6.29e-03	37	60	2	IPR001839
Domain	BROMODOMAIN_1	TAF1 TAF1L	6.29e-03	37	60	2	PS00633
Domain	TGF_BETA_2	BMP3 GDF10	6.29e-03	37	60	2	PS51362
Domain	TGF_beta	BMP3 GDF10	6.29e-03	37	60	2	PF00019
Domain	TGF_BETA_1	BMP3 GDF10	6.29e-03	37	60	2	PS00250
Pathway	REACTOME_O_LINKED_GLYCOSYLATION	ADAMTS12 THSD7A ADAMTS13 MUC2 SSPOP MUC5AC	5.77e-07	109	40	6	MM15164
Pathway	REACTOME_DISEASES_ASSOCIATED_WITH_O_GLYCOSYLATION_OF_PROTEINS	ADAMTS12 THSD7A ADAMTS13 SSPOP MUC5AC	1.30e-06	68	40	5	M27303
Pathway	REACTOME_O_GLYCOSYLATION_OF_TSR_DOMAIN_CONTAINING_PROTEINS	ADAMTS12 THSD7A ADAMTS13 SSPOP	4.25e-06	39	40	4	M27417
Pathway	REACTOME_O_GLYCOSYLATION_OF_TSR_DOMAIN_CONTAINING_PROTEINS	ADAMTS12 THSD7A ADAMTS13 SSPOP	4.25e-06	39	40	4	MM15165
Pathway	REACTOME_O_LINKED_GLYCOSYLATION	ADAMTS12 THSD7A ADAMTS13 SSPOP MUC5AC	1.46e-05	111	40	5	M27416
Pathway	REACTOME_NCAM_SIGNALING_FOR_NEURITE_OUT_GROWTH	CACNA1C COL9A2 HRAS CACNA1I	2.93e-05	63	40	4	M11187
Pathway	REACTOME_DISEASES_OF_GLYCOSYLATION	ADAMTS12 THSD7A ADAMTS13 SSPOP MUC5AC	4.95e-05	143	40	5	M27275
Pathway	REACTOME_DEFECTS_OF_PLATELET_ADHESION_TO_EXPOSED_COLLAGEN	VWF ADAMTS13	2.17e-04	8	40	2	M48236
Pathway	REACTOME_NCAM1_INTERACTIONS	CACNA1C COL9A2 CACNA1I	2.25e-04	42	40	3	M7169
Pathway	WP_IL11_SIGNALING	PTPN11 PIAS3 HRAS	2.59e-04	44	40	3	M39716
Pathway	WP_MECP2_AND_ASSOCIATED_RETT_SYNDROME	MYT1 TAF1 TAF1L	2.95e-04	46	40	3	MM15949
Pathway	REACTOME_SIGNALING_BY_EGFR	PTPN11 PTPRK HRAS	3.56e-04	49	40	3	MM14695
Pathway	REACTOME_ACTIVATED_NTRK2_SIGNALS_THROUGH_FRS2_AND_FRS3	PTPN11 HRAS	4.25e-04	11	40	2	M27911
Pathway	REACTOME_SIGNALING_BY_EGFR	PTPN11 PTPRK HRAS	4.49e-04	53	40	3	M27039
Pathway	REACTOME_PLATELET_ADHESION_TO_EXPOSED_COLLAGEN	VWF ADAMTS13	5.09e-04	12	40	2	MM15452
Pathway	REACTOME_SIGNALING_BY_PDGF	COL9A2 PTPN11 HRAS	5.57e-04	57	40	3	MM14713
Pathway	REACTOME_SIGNALING_BY_PDGF	COL9A2 PTPN11 HRAS	5.86e-04	58	40	3	M2049
Pathway	WP_COMPLEMENT_AND_COAGULATION_CASCADES	VWF CR2 MASP2	5.86e-04	58	40	3	M39649
Pathway	WP_DENGUE2_INTERACTIONS_WITH_COMPLEMENT_AND_COAGULATION_CASCADES	VWF CR2 MASP2	6.16e-04	59	40	3	M48343
Pathway	REACTOME_DISEASES_OF_METABOLISM	ADAMTS12 THSD7A ADAMTS13 SSPOP MUC5AC	6.68e-04	250	40	5	M27554
Pathway	REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION	COL9A2 VWF PXDN ADAM15 LAMA4	7.70e-04	258	40	5	MM14572
Pathway	WP_ONCOSTATIN_M_SIGNALING	PTPN11 PIAS3 HRAS	8.18e-04	65	40	3	M39562
Pathway	REACTOME_SIGNALING_BY_MET	PTPN11 HRAS LAMA4	8.94e-04	67	40	3	MM15345
Pathway	REACTOME_PLATELET_ADHESION_TO_EXPOSED_COLLAGEN	VWF ADAMTS13	9.19e-04	16	40	2	M9450
Pathway	REACTOME_SIGNALING_BY_FLT3_ITD_AND_TKD_MUTANTS	PTPN11 HRAS	9.19e-04	16	40	2	M41733
Pathway	KEGG_COMPLEMENT_AND_COAGULATION_CASCADES	VWF CR2 MASP2	9.74e-04	69	40	3	M16894
Pathway	BIOCARTA_PML_PATHWAY	SP100 HRAS	1.04e-03	17	40	2	M4891
Pathway	REACTOME_TIE2_SIGNALING	PTPN11 HRAS	1.04e-03	17	40	2	MM14836
Pathway	WP_EGFEGFR_SIGNALING	PTPN11 PXDN PIAS3 HRAS	1.11e-03	162	40	4	M39334
Pathway	BIOCARTA_PML_PATHWAY	SP100 HRAS	1.17e-03	18	40	2	MM1474
Pathway	BIOCARTA_MPR_PATHWAY	MYT1 HRAS	1.17e-03	18	40	2	MM1407
Pathway	REACTOME_TIE2_SIGNALING	PTPN11 HRAS	1.17e-03	18	40	2	M11932
Pathway	WP_PROLACTIN_SIGNALING	PTPN11 PIAS3 HRAS	1.29e-03	76	40	3	M39601
Pathway	REACTOME_DISEASES_OF_HEMOSTASIS	VWF ADAMTS13	1.30e-03	19	40	2	M48230
Pathway	REACTOME_FRS_MEDIATED_FGFR3_SIGNALING	PTPN11 HRAS	1.30e-03	19	40	2	MM15245
Pathway	REACTOME_SIGNALING_BY_MET	PTPN11 HRAS LAMA4	1.44e-03	79	40	3	M27643
Pathway	REACTOME_FRS_MEDIATED_FGFR3_SIGNALING	PTPN11 HRAS	1.44e-03	20	40	2	M27519
Pathway	REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION	COL9A2 VWF PXDN ADAM15 LAMA4	1.51e-03	300	40	5	M610
Pathway	KEGG_MEDICUS_REFERENCE_ACH_CHRN_RAS_ERK_SIGNALING_PATHWAY	HRAS ATF6B	1.59e-03	21	40	2	M47792
Pathway	REACTOME_TERMINATION_OF_O_GLYCAN_BIOSYNTHESIS	MUC2 MUC5AC	1.59e-03	21	40	2	MM15706
Pathway	BIOCARTA_IGF1_PATHWAY	PTPN11 HRAS	1.59e-03	21	40	2	M2623
Pathway	BIOCARTA_MPR_PATHWAY	MYT1 HRAS	1.59e-03	21	40	2	M13883
Pathway	BIOCARTA_IL6_PATHWAY	PTPN11 HRAS	1.59e-03	21	40	2	M5489
Pathway	REACTOME_FRS_MEDIATED_FGFR4_SIGNALING	PTPN11 HRAS	1.59e-03	21	40	2	MM15248
Pathway	BIOCARTA_INSULIN_PATHWAY	PTPN11 HRAS	1.59e-03	21	40	2	M765
Pathway	REACTOME_COMPLEMENT_CASCADE	CR2 MASP2 CFHR4	1.72e-03	84	40	3	MM14653
Pathway	REACTOME_FRS_MEDIATED_FGFR4_SIGNALING	PTPN11 HRAS	1.75e-03	22	40	2	M27522
Pathway	BIOCARTA_IGF1_PATHWAY	PTPN11 HRAS	1.75e-03	22	40	2	MM1409
Pathway	BIOCARTA_IL6_PATHWAY	PTPN11 HRAS	1.75e-03	22	40	2	MM1415
Pathway	REACTOME_FRS_MEDIATED_FGFR1_SIGNALING	PTPN11 HRAS	1.75e-03	22	40	2	MM15239
Pathway	REACTOME_FRS_MEDIATED_FGFR1_SIGNALING	PTPN11 HRAS	1.91e-03	23	40	2	M27513
Pathway	KEGG_MEDICUS_REFERENCE_E2_ER_RAS_ERK_SIGNALING_PATHWAY	HRAS ATF6B	1.91e-03	23	40	2	M47799
Pathway	KEGG_MEDICUS_REFERENCE_VGCC_CA2_APOPTOTIC_PATHWAY	CACNA1C CACNA1I	1.91e-03	23	40	2	M47666
Pathway	REACTOME_FRS_MEDIATED_FGFR2_SIGNALING	PTPN11 HRAS	1.91e-03	23	40	2	MM15243
Pathway	BIOCARTA_INSULIN_PATHWAY	PTPN11 HRAS	2.08e-03	24	40	2	MM1425
Pathway	REACTOME_DOWNSTREAM_SIGNALING_OF_ACTIVATED_FGFR3	PTPN11 HRAS	2.08e-03	24	40	2	MM15246
Pathway	BIOCARTA_TFF_PATHWAY	HRAS MUC2	2.08e-03	24	40	2	M15926
Pathway	REACTOME_FRS_MEDIATED_FGFR2_SIGNALING	PTPN11 HRAS	2.26e-03	25	40	2	M27517
Pathway	REACTOME_DOWNSTREAM_SIGNALING_OF_ACTIVATED_FGFR3	PTPN11 HRAS	2.26e-03	25	40	2	M27520
Pathway	REACTOME_SIGNALING_BY_NTRK2_TRKB	PTPN11 HRAS	2.26e-03	25	40	2	M27864
Pathway	KEGG_MEDICUS_REFERENCE_CA2_ENTRY_VOLTAGE_GATED_CA2_CHANNEL	CACNA1C CACNA1I	2.26e-03	25	40	2	M47948
Pathway	WP_FOCAL_ADHESION	VWF HRAS LAMA4 ZYX	2.37e-03	199	40	4	M39402
Pathway	KEGG_FOCAL_ADHESION	VWF HRAS LAMA4 ZYX	2.37e-03	199	40	4	M7253
Pathway	REACTOME_DOWNSTREAM_SIGNALING_OF_ACTIVATED_FGFR4	PTPN11 HRAS	2.44e-03	26	40	2	MM15249
Pathway	WP_COMPLEMENT_SYSTEM	CR2 MASP2 CFHR4	2.52e-03	96	40	3	M39581
Pathway	WP_PI3KAKT_SIGNALING	COL9A2 VWF HRAS LAMA4 ATF6B	2.57e-03	339	40	5	M39736
Pathway	WP_B_CELL_RECEPTOR_SIGNALING	PTPN11 HRAS CR2	2.59e-03	97	40	3	M39323
Pathway	REACTOME_DOWNSTREAM_SIGNALING_OF_ACTIVATED_FGFR4	PTPN11 HRAS	2.63e-03	27	40	2	M27523
Pathway	REACTOME_DOWNSTREAM_SIGNAL_TRANSDUCTION	PTPN11 HRAS	2.63e-03	27	40	2	MM14712
Pathway	REACTOME_FLT3_SIGNALING_IN_DISEASE	PTPN11 HRAS	2.83e-03	28	40	2	M41724
Pathway	REACTOME_DOWNSTREAM_SIGNALING_OF_ACTIVATED_FGFR2	PTPN11 HRAS	2.83e-03	28	40	2	MM15241
Pathway	BIOCARTA_TFF_PATHWAY	HRAS MUC2	3.04e-03	29	40	2	MM1522
Pathway	PID_IGF1_PATHWAY	PTPN11 HRAS	3.04e-03	29	40	2	M125
Pathway	REACTOME_DOWNSTREAM_SIGNAL_TRANSDUCTION	PTPN11 HRAS	3.04e-03	29	40	2	M779
Pathway	REACTOME_DOWNSTREAM_SIGNALING_OF_ACTIVATED_FGFR2	PTPN11 HRAS	3.25e-03	30	40	2	M27515
Pathway	REACTOME_DOWNSTREAM_SIGNALING_OF_ACTIVATED_FGFR1	PTPN11 HRAS	3.25e-03	30	40	2	MM15236
Pathway	WP_PROSTAGLANDIN_AND_LEUKOTRIENE_METABOLISM_IN_SENESCENCE_WP5122	IGFBP5 HRAS	3.47e-03	31	40	2	M42531
Pathway	REACTOME_DOWNSTREAM_SIGNALING_OF_ACTIVATED_FGFR1	PTPN11 HRAS	3.47e-03	31	40	2	M27510
Pathway	PID_EPO_PATHWAY	PTPN11 HRAS	3.92e-03	33	40	2	M233
Pathway	WP_ALPHA_6_BETA_4_SIGNALING	PTPN11 HRAS	3.92e-03	33	40	2	M39503
Pathway	BIOCARTA_MET_PATHWAY	PTPN11 HRAS	3.92e-03	33	40	2	M19358
Pathway	BIOCARTA_INTEGRIN_PATHWAY	HRAS ZYX	3.92e-03	33	40	2	MM1426
Pathway	BIOCARTA_MET_PATHWAY	PTPN11 HRAS	3.92e-03	33	40	2	MM1494
Pathway	WP_PROSTAGLANDIN_AND_LEUKOTRIENE_METABOLISM_IN_SENESCENCE_WP5321	IGFBP5 HRAS	4.16e-03	34	40	2	M48061
Pathway	BIOCARTA_INTEGRIN_PATHWAY	HRAS ZYX	4.16e-03	34	40	2	M3342
Pathway	WP_HEPATOCYTE_GROWTH_FACTOR_RECEPTOR_SIGNALING	PTPN11 HRAS	4.16e-03	34	40	2	M39383
Pathway	REACTOME_COMPLEMENT_CASCADE	CR2 MASP2 CFHR4	4.19e-03	115	40	3	M19752
Pathway	KEGG_BASAL_TRANSCRIPTION_FACTORS	TAF1 TAF1L	4.40e-03	35	40	2	M4864
Pathway	PID_ERBB1_RECEPTOR_PROXIMAL_PATHWAY	PTPN11 HRAS	4.40e-03	35	40	2	M127
Pubmed	Extracellular matrix secretion by cardiac fibroblasts: role of microRNA-29b and microRNA-30c.	SSC5D VWF PXDN ADAM15 LAMA4 ATF6B SVEP1 CFHR4	1.65e-08	248	63	8	24006456
Pubmed	Plasma ADAMTS13 activity and von Willebrand factor antigen and activity in patients with subarachnoid haemorrhage.	VWF ADAMTS13	3.23e-06	2	63	2	28102428
Pubmed	Intestinal MUC2 and gastric M1/MUC5AC in preneoplastic lesions induced by 1,2-dimethylhydrazine in rat: a sequential analysis.	MUC2 MUC5AC	3.23e-06	2	63	2	17203232
Pubmed	The association between the L1565 variant of von Willebrand factor and susceptibility to proteolysis by ADAMTS13.	VWF ADAMTS13	3.23e-06	2	63	2	17296575
Pubmed	Interrelationship between ADAMTS13 activity, von Willebrand factor, and complement activation in remission from immune-mediated trhrombotic thrombocytopenic purpura.	VWF ADAMTS13	3.23e-06	2	63	2	32065383
Pubmed	Protective effect of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 haplotype on coronary artery disease.	VWF ADAMTS13	3.23e-06	2	63	2	27536857
Pubmed	ADAMTS13 gene deletion aggravates ischemic brain damage: a possible neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion.	VWF ADAMTS13	3.23e-06	2	63	2	19965676
Pubmed	Carboxyl terminus of ADAMTS13 directly inhibits platelet aggregation and ultra large von Willebrand factor string formation under flow in a free-thiol-dependent manner.	VWF ADAMTS13	3.23e-06	2	63	2	24357063
Pubmed	ADAMTS13 and Von Willebrand factor in patients undergoing hemodialysis.	VWF ADAMTS13	3.23e-06	2	63	2	22298244
Pubmed	Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal?	DPP9 DPP8	3.23e-06	2	63	2	21711053
Pubmed	Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease.	VWF ADAMTS13	3.23e-06	2	63	2	28591212
Pubmed	Identifying natural substrates for dipeptidyl peptidases 8 and 9 using terminal amine isotopic labeling of substrates (TAILS) reveals in vivo roles in cellular homeostasis and energy metabolism.	DPP9 DPP8	3.23e-06	2	63	2	23519473
Pubmed	Profibrotic mechanisms of DPP8 and DPP9 highly expressed in the proximal renal tubule epithelial cells.	DPP9 DPP8	3.23e-06	2	63	2	33932609
Pubmed	ADAMTS13 deficiency exacerbates VWF-dependent acute myocardial ischemia/reperfusion injury in mice.	VWF ADAMTS13	3.23e-06	2	63	2	22983446
Pubmed	Obstetric outcomes in pregnant COVID-19 women: the imbalance of von Willebrand factor and ADAMTS13 axis.	VWF ADAMTS13	3.23e-06	2	63	2	35189860
Pubmed	Increased von Willebrand factor antigen and low ADAMTS13 activity are related to poor prognosis in covid-19 patients.	VWF ADAMTS13	3.23e-06	2	63	2	33502080
Pubmed	N-Glycans of ADAMTS13 modulate its secretion and von Willebrand factor cleaving activity.	VWF ADAMTS13	3.23e-06	2	63	2	18981290
Pubmed	The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor.	VWF ADAMTS13	3.23e-06	2	63	2	15975930
Pubmed	[Application Value of Plasma vWF and ADAMTS-13 in Evaluating Postoprative Vascular Endothelial Injury and Prognosis in Children with VSD].	VWF ADAMTS13	3.23e-06	2	63	2	36765498
Pubmed	Amino acid residues Arg(659), Arg(660), and Tyr(661) in the spacer domain of ADAMTS13 are critical for cleavage of von Willebrand factor.	VWF ADAMTS13	3.23e-06	2	63	2	20075158
Pubmed	Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state.	VWF ADAMTS13	3.23e-06	2	63	2	28457019
Pubmed	A conformation-sensitive monoclonal antibody against the A2 domain of von Willebrand factor reduces its proteolysis by ADAMTS13.	VWF ADAMTS13	3.23e-06	2	63	2	21779388
Pubmed	Role of chloride ions in modulation of the interaction between von Willebrand factor and ADAMTS-13.	VWF ADAMTS13	3.23e-06	2	63	2	15809291
Pubmed	Platelet-free shear flow assay facilitates analysis of shear-dependent functions of VWF and ADAMTS13.	VWF ADAMTS13	3.23e-06	2	63	2	25201004
Pubmed	Interactions of von Willebrand factor and ADAMTS13 in von Willebrand disease and thrombotic thrombocytopenic purpura.	VWF ADAMTS13	3.23e-06	2	63	2	25010251
Pubmed	Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis.	PTPN11 HRAS	3.23e-06	2	63	2	26617336
Pubmed	Von Willebrand factor and ADAMTS13: a candidate couple for preeclampsia pathophysiology.	VWF ADAMTS13	3.23e-06	2	63	2	21512165
Pubmed	Von Willebrand Factor, ADAMTS13 and D-Dimer Are Correlated with Different Levels of Nephropathy in Type 1 Diabetes Mellitus.	VWF ADAMTS13	3.23e-06	2	63	2	26168189
Pubmed	Multi-step binding of ADAMTS-13 to von Willebrand factor.	VWF ADAMTS13	3.23e-06	2	63	2	19765212
Pubmed	FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients.	VWF ADAMTS13	3.23e-06	2	63	2	24740645
Pubmed	Endothelial Cell-Derived von Willebrand Factor Is the Major Determinant That Mediates von Willebrand Factor-Dependent Acute Ischemic Stroke by Promoting Postischemic Thrombo-Inflammation.	VWF ADAMTS13	3.23e-06	2	63	2	27444201
Pubmed	Ratio of von Willebrand factor propeptide to ADAMTS13 is associated with severity of sepsis.	VWF ADAMTS13	3.23e-06	2	63	2	23481506
Pubmed	Inhibition of dipeptidyl peptidase 8/9 impairs preadipocyte differentiation.	DPP9 DPP8	3.23e-06	2	63	2	26242871
Pubmed	Expression profiling of dipeptidyl peptidase 8 and 9 in breast and ovarian carcinoma cell lines.	DPP9 DPP8	3.23e-06	2	63	2	22736146
Pubmed	Altered glycosylation of platelet-derived von Willebrand factor confers resistance to ADAMTS13 proteolysis.	VWF ADAMTS13	3.23e-06	2	63	2	24106205
Pubmed	[Increased susceptibility of recombinant type 2A von Willebrand factor mutant A1500E to proteolysis by ADAMTS13].	VWF ADAMTS13	3.23e-06	2	63	2	22781599
Pubmed	Development of a severe von Willebrand factor/ADAMTS13 dysbalance during orthotopic liver transplantation.	VWF ADAMTS13	3.23e-06	2	63	2	19422343
Pubmed	Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells.	VWF ADAMTS13	3.23e-06	2	63	2	18433458
Pubmed	Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure.	VWF ADAMTS13	3.23e-06	2	63	2	19190805
Pubmed	Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia.	VWF ADAMTS13	3.23e-06	2	63	2	19190814
Pubmed	ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men.	VWF ADAMTS13	3.23e-06	2	63	2	17053057
Pubmed	Characterization of ADAMTS13 and von Willebrand factor levels in septic and non-septic ICU patients.	VWF ADAMTS13	3.23e-06	2	63	2	33606732
Pubmed	Methylation status of promoters and expression of MUC2 and MUC5AC mucins in pancreatic cancer cells.	MUC2 MUC5AC	3.23e-06	2	63	2	12527922
Pubmed	Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B.	VWF ADAMTS13	3.23e-06	2	63	2	20200350
Pubmed	von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke.	VWF ADAMTS13	3.23e-06	2	63	2	19687510
Pubmed	Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage.	VWF ADAMTS13	3.23e-06	2	63	2	22431572
Pubmed	Von Willebrand factor and ADAMTS13 activity in relation to risk of dementia: a population-based study.	VWF ADAMTS13	3.23e-06	2	63	2	29615758
Pubmed	Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack.	VWF ADAMTS13	3.23e-06	2	63	2	18194418
Pubmed	von Willebrand factor/ADAMTS13 ratio at presentation of acute ischemic brain injury is predictive of outcome.	VWF ADAMTS13	3.23e-06	2	63	2	31990334
Pubmed	DPP8/9 inhibition attenuates the TGF-β1-induced excessive deposition of extracellular matrix (ECM) in human mesangial cells via Smad and Akt signaling pathways.	DPP9 DPP8	3.23e-06	2	63	2	38458339
Pubmed	Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13.	VWF ADAMTS13	3.23e-06	2	63	2	19812385
Pubmed	ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock.	VWF ADAMTS13	3.23e-06	2	63	2	17764538
Pubmed	Role of von Willebrand factor and ADAMTS-13 in early brain injury after experimental subarachnoid hemorrhage.	VWF ADAMTS13	3.23e-06	2	63	2	29729651
Pubmed	ADAMTS13-von Willebrand factor axis is involved in the pathophysiology of kidney ischaemia-reperfusion injury.	VWF ADAMTS13	3.23e-06	2	63	2	27507004
Pubmed	Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions.	VWF ADAMTS13	3.23e-06	2	63	2	16141351
Pubmed	Change in plasma a disintegrin and metalloprotease with thrombospondin type-1 repeats-13 and von Willebrand factor levels in venous thromboembolic patients.	VWF ADAMTS13	3.23e-06	2	63	2	26872106
Pubmed	Keeping von Willebrand Factor under Control: Alternatives for ADAMTS13.	VWF ADAMTS13	3.23e-06	2	63	2	26595154
Pubmed	Domain-specific mechanical modulation of VWF-ADAMTS13 interaction.	VWF ADAMTS13	3.23e-06	2	63	2	31067148
Pubmed	Mechanism of von Willebrand factor scissile bond cleavage by a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13).	VWF ADAMTS13	3.23e-06	2	63	2	21705658
Pubmed	Insights Into Immunothrombosis: The Interplay Among Neutrophil Extracellular Trap, von Willebrand Factor, and ADAMTS13.	VWF ADAMTS13	3.23e-06	2	63	2	33343584
Pubmed	Zinc and calcium ions cooperatively modulate ADAMTS13 activity.	VWF ADAMTS13	3.23e-06	2	63	2	16286459
Pubmed	von Willebrand factor self-association is regulated by the shear-dependent unfolding of the A2 domain.	VWF ADAMTS13	3.23e-06	2	63	2	30936056
Pubmed	von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans.	VWF ADAMTS13	3.23e-06	2	63	2	25977583
Pubmed	Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS-13.	VWF ADAMTS13	3.23e-06	2	63	2	17087728
Pubmed	Single particle tracking of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type-1 repeats) molecules on endothelial von Willebrand factor strings.	VWF ADAMTS13	3.23e-06	2	63	2	24550384
Pubmed	Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis.	VWF ADAMTS13	3.23e-06	2	63	2	16322474
Pubmed	The complete cDNA sequence and structural polymorphism of the polypeptide chain of porcine submaxillary mucin.	VWF MUC2	3.23e-06	2	63	2	9407109
Pubmed	An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF.	VWF ADAMTS13	3.23e-06	2	63	2	20032502
Pubmed	The ADAMTS13-von Willebrand factor axis in COVID-19 patients.	VWF ADAMTS13	3.23e-06	2	63	2	33230904
Pubmed	Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosis.	VWF ADAMTS13	3.23e-06	2	63	2	25113276
Pubmed	von Willebrand factor enhances microvesicle-induced vascular leakage and coagulopathy in mice with traumatic brain injury.	VWF ADAMTS13	3.23e-06	2	63	2	29941674
Pubmed	Development of a Hyperactive Primary Hemostatic System During Off-Pump Lung Transplantation Resulting From an Unbalance Between von Willebrand Factor and Its Cleaving Protease ADAMTS13.	VWF ADAMTS13	3.23e-06	2	63	2	25846964
Pubmed	The Role of von Willebrand Factor, ADAMTS13, and Cerebral Artery Thrombus Composition in Patient Outcome Following Mechanical Thrombectomy for Acute Ischemic Stroke.	VWF ADAMTS13	3.23e-06	2	63	2	29887594
Pubmed	Force-induced cleavage of single VWFA1A2A3 tridomains by ADAMTS-13.	VWF ADAMTS13	3.23e-06	2	63	2	19897584
Pubmed	ADAMTS13 substrate recognition of von Willebrand factor A2 domain.	VWF ADAMTS13	3.23e-06	2	63	2	16221672
Pubmed	Impact of the von Willebrand factor-ADAMTS-13 axis on the risk of future venous thromboembolism.	VWF ADAMTS13	3.23e-06	2	63	2	36736832
Pubmed	Traumatic injury results in prolonged circulation of ultralarge von Willebrand factor and a reduction in ADAMTS13 activity.	VWF ADAMTS13	3.23e-06	2	63	2	32441353
Pubmed	Secretion of von Willebrand Factor and Suppression of ADAMTS-13 Activity by Markedly High Concentration of Ferritin.	VWF ADAMTS13	3.23e-06	2	63	2	33539188
Pubmed	The p.R1819_C1948delinsS mutation makes von Willebrand factor ADAMTS13-resistant and reduces its collagen-binding capacity.	VWF ADAMTS13	3.23e-06	2	63	2	25904363
Pubmed	ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor.	VWF ADAMTS13	3.23e-06	2	63	2	12775718
Pubmed	Altered von Willebrand Factor and ADAMTS13 Levels in Children With Cirrhosis and Extrahepatic Portal Hypertension.	VWF ADAMTS13	3.23e-06	2	63	2	33369998
Pubmed	Decreased von Willebrand factor ristocetin cofactor activity and increased ADAMTS13 antigen increase postoperative drainage after coronary artery bypass grafting.	VWF ADAMTS13	3.23e-06	2	63	2	24351199
Pubmed	Disulfide bond reduction of von Willebrand factor by ADAMTS-13.	VWF ADAMTS13	3.23e-06	2	63	2	20946172
Pubmed	Src homology 2-containing protein tyrosine phosphatase-2 acts as a negative regulator for MUC5AC transcription via the inhibition of the ERK1/2 MAPK signalling pathway in the airway.	PTPN11 MUC5AC	3.23e-06	2	63	2	23582017
Pubmed	Smoking, von Willebrand factor and ADAMTS-13 in healthy males.	VWF ADAMTS13	3.23e-06	2	63	2	23020229
Pubmed	Allosteric activation of ADAMTS13 by von Willebrand factor.	VWF ADAMTS13	3.23e-06	2	63	2	25512528
Pubmed	Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies: a novel therapeutic strategy?	VWF ADAMTS13	3.23e-06	2	63	2	16203734
Pubmed	ADAMTS13 controls vascular remodeling by modifying VWF reactivity during stroke recovery.	VWF ADAMTS13	3.23e-06	2	63	2	28428179
Pubmed	Identification of ADAMTS13 peptide sequences binding to von Willebrand factor.	VWF ADAMTS13	3.23e-06	2	63	2	19944670
Pubmed	ADAMTS-13 cleaves long von Willebrand factor multimeric strings anchored to endothelial cells in the absence of flow, platelets or conformation-altering chemicals.	VWF ADAMTS13	3.23e-06	2	63	2	18983500
Pubmed	Unconjugated bilirubin inhibits proteolytic cleavage of von Willebrand factor by ADAMTS13 protease.	VWF ADAMTS13	3.23e-06	2	63	2	25782102
Pubmed	Von Willebrand Factor Adhesive Activity and ADAMTS13 Protease Activity in HIV-1-Infected Men.	VWF ADAMTS13	3.23e-06	2	63	2	30745808
Pubmed	Mucolytic activity of bacterial and human chitinases.	MUC2 MUC5AC	3.23e-06	2	63	2	17321686
Pubmed	Taf1 knockout is lethal in embryonic male mice and heterozygous females show weight and movement disorders.	TAF1 TAF1L	3.23e-06	2	63	2	38804708
Pubmed	Activity of Von Willebrand factor and levels of VWF-cleaving protease (ADAMTS13) in preterm and full term neonates.	VWF ADAMTS13	3.23e-06	2	63	2	28087247
Pubmed	ADAMTS-13-VWF axis in sickle cell disease patients.	VWF ADAMTS13	3.23e-06	2	63	2	33404693
Pubmed	Altered expression of MUC2 and MUC5AC in progression of colorectal carcinoma.	MUC2 MUC5AC	3.23e-06	2	63	2	20731025
Pubmed	DP8 and DP9 have extra-enzymatic roles in cell adhesion, migration and apoptosis.	DPP9 DPP8	3.23e-06	2	63	2	16700509
Pubmed	A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF.	VWF ADAMTS13	3.23e-06	2	63	2	19587373
Pubmed	Molecular mapping of the chloride-binding site in von Willebrand factor (VWF): energetics and conformational effects on the VWF/ADAMTS-13 interaction.	VWF ADAMTS13	3.23e-06	2	63	2	16899464
Cytoband	11p15.5	HRAS MUC2 MUC5AC	5.87e-04	118	63	3	11p15.5
Cytoband	12p13.3	CACNA1C VWF	7.86e-04	30	63	2	12p13.3
Cytoband	1q32	CR2 CFHR4	2.09e-03	49	63	2	1q32
GeneFamily	Hyalectan proteoglycans\|V-set domain containing\|Sushi domain containing\|C-type lectin domain containing	SRPX CR2 SEZ6L2 SVEP1 MASP2 CFHR4	4.17e-09	57	43	6	1179
GeneFamily	CD molecules\|DASH family	DPP9 DPP8	1.15e-04	7	43	2	1205
GeneFamily	ADAM metallopeptidases with thrombospondin type 1 motif	ADAMTS12 ADAMTS13	9.21e-04	19	43	2	50
GeneFamily	CD molecules\|Mucins	MUC2 MUC5AC	1.13e-03	21	43	2	648
GeneFamily	Calcium voltage-gated channel subunits	CACNA1C CACNA1I	1.73e-03	26	43	2	253
GeneFamily	Complement system\|Sushi domain containing	CR2 CFHR4	3.31e-03	36	43	2	492
Coexpression	NABA_MATRISOME	ADAMTS12 BMP3 COL9A2 VWF PXDN IGFBP5 ADAM15 KCP LAMA4 ADAMTS13 SRPX GDF10 MUC2 SSPOP MUC5AC SVEP1 MASP2	1.11e-10	1008	62	17	MM17056
Coexpression	NABA_MATRISOME	ADAMTS12 BMP3 COL9A2 VWF PXDN IGFBP5 ADAM15 KCP LAMA4 ADAMTS13 SRPX GDF10 MUC2 SSPOP MUC5AC SVEP1 MASP2	1.47e-10	1026	62	17	M5889
Coexpression	NABA_CORE_MATRISOME	COL9A2 VWF PXDN IGFBP5 KCP LAMA4 SRPX SSPOP SVEP1	1.44e-08	270	62	9	MM17057
Coexpression	NABA_ECM_GLYCOPROTEINS	VWF PXDN IGFBP5 KCP LAMA4 SRPX SSPOP SVEP1	1.66e-08	191	62	8	MM17059
Coexpression	NABA_CORE_MATRISOME	COL9A2 VWF PXDN IGFBP5 KCP LAMA4 SRPX SSPOP SVEP1	1.69e-08	275	62	9	M5884
Coexpression	NABA_ECM_GLYCOPROTEINS	VWF PXDN IGFBP5 KCP LAMA4 SRPX SSPOP SVEP1	2.03e-08	196	62	8	M3008
Coexpression	GSE22527_ANTI_CD3_INVIVO_VS_UNTREATED_MOUSE_TREG_UP	CACNA1C SP100 CACNA1I MUC2 MUC5AC ZYX CASZ1	4.52e-07	199	62	7	M7710
Coexpression	VERRECCHIA_RESPONSE_TO_TGFB1_C3	IGFBP5 LAMA4 ZYX	4.50e-06	14	62	3	M5321
Coexpression	MANNO_MIDBRAIN_NEUROTYPES_HPERIC	CACNA1C PXDN PTPRK KCP LAMA4 NR4A3 SRPX TNFRSF21 ZYX SVEP1	1.61e-05	795	62	10	M39050
Coexpression	BROWNE_HCMV_INFECTION_48HR_DN	CACNA1C PTPN11 IGFBP5 HRAS TAF1 GDF10 ZYX SVEP1	1.75e-05	482	62	8	M12144
Coexpression	MANNO_MIDBRAIN_NEUROTYPES_HGABA	CACNA1C THSD7A RAPH1 PTPRK ASXL3 MYT1 CACNA1I SEZ6L2 MUC2 SSPOP CASZ1	5.06e-05	1106	62	11	M39071
Coexpression	BRUINS_UVC_RESPONSE_LATE	CACNA1C PTPN11 PXDN PTPRK HRAS LAMA4 SRPX DPP8 SH3D21 SVEP1 TCEAL1	6.44e-05	1136	62	11	M2247
Coexpression	BRUINS_UVC_RESPONSE_LATE	CACNA1C PTPN11 PXDN PTPRK HRAS LAMA4 SRPX DPP8 SH3D21 SVEP1 TCEAL1	1.03e-04	1198	62	11	MM1062
Coexpression	GSE19888_NO_PRETREAT_VS_ADENOSINE_A3R_INHIBITOR_PRETREATED_MAST_CELL_TCELL_MEMBRANES_ACT_DN	PXDN DPP9 NFXL1 BAHD1 PRKRA	1.12e-04	200	62	5	M7347
CoexpressionAtlas	gudmap_RNAseq_e15.5_Podocytes_2500_K0	ADAMTS12 VWF THSD7A ADAM15 HRAS LAMA4 SRPX R3HDML SEZ6L2 TMEM52B ZYX CASZ1 SF3B5	1.74e-05	1143	61	13	gudmap_RNAseq_e15.5_Podocytes_2500_K0
CoexpressionAtlas	Stromal Cells, FRC.MLN, gp38+ CD31- CD140a+, Lymph Node, avg-5	ADAMTS12 PXDN THSD7A IGFBP5 LAMA4 SRPX GDF10 SVEP1	5.38e-05	466	61	8	GSM777050_500
ToppCell	facs-Mammary_Gland-Mammary_Gland-3m-Mesenchymal-stromal_cell\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ADAMTS12 SSC5D SP100 LAMA4 SRPX SVEP1	2.26e-07	185	62	6	3cd0686a14e734a0f243070ab939adcb4c454478
ToppCell	facs-Mammary_Gland-Mammary_Gland-3m-Mesenchymal-stromal_cell\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ADAMTS12 SSC5D SP100 LAMA4 SRPX SVEP1	2.26e-07	185	62	6	00258f458cbf6d36449db95528a6b5038d731d2d
ToppCell	facs-Mammary_Gland-Mammary_Gland-3m-Mesenchymal\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ADAMTS12 SSC5D SP100 LAMA4 SRPX SVEP1	2.26e-07	185	62	6	a94694e226856bc5b168464f52d76004145717a5
ToppCell	facs-Kidney-nan-3m-Mesenchymal-mesangial_cell\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ADAMTS12 CACNA1C BMP3 SRPX GDF10 SVEP1	2.57e-07	189	62	6	a5306561026e4dfcc39beeb785e5108ac595d136
ToppCell	facs-Kidney-nan-3m-Mesenchymal\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ADAMTS12 CACNA1C BMP3 SRPX GDF10 SVEP1	2.57e-07	189	62	6	381058f55908f84375b54601d617389ef43ab855
ToppCell	facs-Kidney-nan-3m-Mesenchymal-mesangial_cell\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ADAMTS12 CACNA1C BMP3 SRPX GDF10 SVEP1	2.57e-07	189	62	6	302b950a6ad578f8aeff7ea6fd15fe631225287d
ToppCell	facs-Heart-LV-3m-Mesenchymal-fibroblast_of_cardiac_tissue\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SSC5D ARSJ THSD7A KCP LAMA4 SVEP1	2.81e-07	192	62	6	671d4e1eee5aba03c43dbc98f4b51ce42b3df5d5
ToppCell	facs-Heart-LV-3m-Mesenchymal-fibroblast_of_cardiac_tissue\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SSC5D ARSJ THSD7A KCP LAMA4 SVEP1	2.81e-07	192	62	6	840a34c1b82d218be999ab5e1bcafd6370d7a4b1
ToppCell	368C-Fibroblasts-Fibroblast-G-\|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells)	TMEM171 IGFBP5 LAMA4 GDF10 ZYX SVEP1	2.99e-07	194	62	6	d9eec28fa7b255c0ec023276dd955f1e276e7159
ToppCell	PCW_07-8.5-Mesenchymal-Mesenchymal_fibroblastic\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	ADAMTS12 CACNA1C IGFBP5 LAMA4 GDF10 SVEP1	2.99e-07	194	62	6	8c37bedb23285735ff3828db3889897fada8c95d
ToppCell	368C-Fibroblasts-Fibroblast-G\|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells)	TMEM171 IGFBP5 LAMA4 GDF10 ZYX SVEP1	2.99e-07	194	62	6	e4d7e9709ce42d4610e44d3445927eefbcbb9eff
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature1_(0)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	ADAMTS12 CACNA1C THSD7A ASXL3 GDF10 SVEP1	3.27e-07	197	62	6	0034bae02ee7fcfea520d453ca3c842ab6963b12
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature1_(0)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	ADAMTS12 CACNA1C THSD7A ASXL3 GDF10 SVEP1	3.27e-07	197	62	6	11a4c417f035e554431a8f03be13b5eefa3530c0
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	ADAMTS12 CACNA1C THSD7A LAMA4 GDF10 SVEP1	3.37e-07	198	62	6	17dc055e2a289496d9c5cdbf3297bdf906dc6d22
ToppCell	Control-Stromal\|Control / Disease state, Lineage and Cell class	CACNA1C PXDN IGFBP5 LAMA4 SRPX SVEP1	3.37e-07	198	62	6	ae726b6b7f0a4107899be4d32ac256ffa0bd8d59
ToppCell	COVID-19-kidney-Fibroblast-2\|kidney / Disease (COVID-19 only), tissue and cell type	ADAMTS12 CACNA1C PXDN LAMA4 NR4A3 SVEP1	3.37e-07	198	62	6	ca26ca460856b1faaa3e83766da6abdf63af2b51
ToppCell	Control_saline-Mesenchymal_fibroblastic-Fibroblasts-Diff_MatrixFB\|Control_saline / Treatment groups by lineage, cell group, cell type	ADAMTS12 LAMA4 SRPX GDF10 ZYX SVEP1	3.47e-07	199	62	6	c2c42ecf20d1924edc2f899c01dfa5fcf3c210b9
ToppCell	10x3'2.3-week_17-19-Mesenchymal_fibro-stroma-arteriolar_fibroblast\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	ADAMTS12 ARSJ IGFBP5 LAMA4 SRPX SVEP1	3.47e-07	199	62	6	95d95e9b7bd3933188998ae94986213eb0f1e5ea
ToppCell	LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	ADAMTS12 LAMA4 SRPX GDF10 ZYX SVEP1	3.47e-07	199	62	6	30d3e8c0681ec11f86dd38c5f48d21187a1b4f90
ToppCell	COVID-19-kidney-Fibroblast-1\|kidney / Disease (COVID-19 only), tissue and cell type	ADAMTS12 CACNA1C PXDN LAMA4 NR4A3 SVEP1	3.47e-07	199	62	6	9503646ff1ad248181146ce767e9d12e882ec3bd
ToppCell	10x3'2.3-week_17-19-Mesenchymal_fibro-stroma\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	ADAMTS12 SSC5D ARSJ IGFBP5 LAMA4 SRPX	3.58e-07	200	62	6	747c61d4e0b746278ae1f45ca4cd556c6961c76a
ToppCell	LPS_only-Mesenchymal_fibroblastic-Fibroblasts-Diff_MatrixFB\|LPS_only / Treatment groups by lineage, cell group, cell type	ADAMTS12 LAMA4 SRPX GDF10 ZYX SVEP1	3.58e-07	200	62	6	ab4fda0cc95cb8f80ea9f28745013f3248def820
ToppCell	Control_saline-Mesenchymal_fibroblastic\|Control_saline / Treatment groups by lineage, cell group, cell type	ADAMTS12 LAMA4 SRPX GDF10 ZYX SVEP1	3.58e-07	200	62	6	64ae5cf6cb4fc94cf1052abd82648f6b8e6445fe
ToppCell	LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	ADAMTS12 LAMA4 SRPX GDF10 ZYX SVEP1	3.58e-07	200	62	6	b79628fd1386aa9a3b0e9fa81def0bc100c3c073
ToppCell	LPS_anti-TNF-Mesenchymal_fibroblastic\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	ADAMTS12 LAMA4 SRPX GDF10 ZYX SVEP1	3.58e-07	200	62	6	50ca6550998e461ef26dd670351060bd940765a8
ToppCell	LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-Diff_MatrixFB\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	ADAMTS12 LAMA4 SRPX GDF10 ZYX SVEP1	3.58e-07	200	62	6	3bdba9612cd7c612b76aa9abecc4a6529aabfc1c
ToppCell	tumor_Lymph_Node_/_Brain-Fibroblasts\|tumor_Lymph_Node_/_Brain / Location, Cell class and cell subclass	ADAMTS12 CACNA1C IGFBP5 LAMA4 SRPX GDF10	3.58e-07	200	62	6	4f7e26b27bd51c32420ed8c2f52d070aee542159
ToppCell	10x3'2.3-week_17-19-Mesenchymal_fibro\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	ADAMTS12 SSC5D ARSJ IGFBP5 LAMA4 SRPX	3.58e-07	200	62	6	de1d193f773f4e2927baa6fc38d29754b015c6e6
ToppCell	LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	ADAMTS12 LAMA4 SRPX GDF10 ZYX SVEP1	3.58e-07	200	62	6	44a68bacdb3d5bf563bd35952176995850933a81
ToppCell	Control_saline-Mesenchymal_fibroblastic-Fibroblasts\|Control_saline / Treatment groups by lineage, cell group, cell type	ADAMTS12 LAMA4 SRPX GDF10 ZYX SVEP1	3.58e-07	200	62	6	a1fc74c1b27e104895910bc7cdce7ba33d30df7e
ToppCell	LPS_IL1RA_TNF-Mesenchymal_fibroblastic\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	ADAMTS12 LAMA4 SRPX GDF10 ZYX SVEP1	3.58e-07	200	62	6	dc61016c61729f69649cfb21f6264e685ce83dea
ToppCell	Control_saline-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|Control_saline / Treatment groups by lineage, cell group, cell type	ADAMTS12 LAMA4 SRPX GDF10 ZYX SVEP1	3.58e-07	200	62	6	bd8cf33502adea320e91ca2af14e1911d88ad374
ToppCell	Adult-Mesenchymal-chondrocyte-D231\|Adult / Lineage, Cell type, age group and donor	ADAMTS12 CACNA1C LAMA4 SEZ6L2 SVEP1	3.31e-06	164	62	5	2ba57dce5f69a88f0d1e450b9780425e2d9ca7d4
ToppCell	-Donor_05\|World / lung cells shred on cell class, cell subclass, sample id	CACNA1C IGFBP5 LAMA4 GDF10 SVEP1	3.84e-06	169	62	5	8ebe9a88111c53a09c25a7b6a164a0a17880458d
ToppCell	PND07-Endothelial-Endothelial_blood-vessel-Macrovascular_EC-VEC-VEC_G2M\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	METTL13 VWF ARSJ BAHD1 MASP2	4.42e-06	174	62	5	6c36d607c48267a75ab4da6fb2fe3f931d1b3b52
ToppCell	primary_visual_cortex-Neuronal-glutamatergic_neuron-L6_IT-L6_IT_VISp_Penk_Fst\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	BMP3 ARSJ PTPRK NR4A3 ADAMTS13	4.67e-06	176	62	5	a1b9f8f199a028b3fa85de43fe96bc29f387bfd8
ToppCell	3'-Child09-12-SmallIntestine-Mesenchymal-fibroblastic-Stromal_4_(MMP1+)\|Child09-12 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	ARSJ PXDN IGFBP5 LAMA4 ADAMTS13	4.81e-06	177	62	5	ac90e4ce5be304a5a7473736397327010f2d1999
ToppCell	TCGA-Colorectal-Primary_Tumor-Colorectal_Adenocarcinoma-Mucinous_Colon_Adenocarcinoma-10\|TCGA-Colorectal / Sample_Type by Project: Shred V9	PXDN THSD7A DOCK8 LAMA4 SVEP1	5.08e-06	179	62	5	cc079ba015326dccde955c5eafa3e4a2e40de192
ToppCell	tumor_Lung-Fibroblasts-Undetermined\|tumor_Lung / Location, Cell class and cell subclass	IGFBP5 LAMA4 SRPX GDF10 SVEP1	5.36e-06	181	62	5	53bcab4d6df4a3255d81877ba22fb95d4492ce9f
ToppCell	primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2-Inh_L1-3_VIP_ZNF322P1\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	PXDN THSD7A IGFBP5 GDF10 SVEP1	5.50e-06	182	62	5	d3a037268f026eb2f84428b1821022503cef7756
ToppCell	COVID-19-Heart-Fib_+_EC_+_Pericyte\|COVID-19 / Disease (COVID-19 only), tissue and cell type	CACNA1C VWF PXDN SRPX SVEP1	5.50e-06	182	62	5	fbd5e332df73bf7141c822fa67b76367dc962017
ToppCell	COVID-19-Heart-EC_3\|COVID-19 / Disease (COVID-19 only), tissue and cell type	CACNA1C VWF THSD7A IGFBP5 ADAM15	5.65e-06	183	62	5	ff95382cfed592190d0636d2b750328471f82e0d
ToppCell	droplet-Lung-3m-Epithelial-airway_epithelial-neuroendocrine_cell\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	TMEM171 COL9A2 TMEM130 R3HDML SEZ6L2	5.80e-06	184	62	5	e0e5a553fb8c0947679634396d20c2ca8455b932
ToppCell	droplet-Kidney-nan-21m-Mesenchymal-fibroblast\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SSC5D LAMA4 SRPX GDF10 SVEP1	5.80e-06	184	62	5	3bffadb0cb2e0d825bdb6cfc5d23f5436cbc3efd
ToppCell	droplet-Lung-3m-Epithelial-airway_epithelial-neuroendocrine_cell-neuroendocrine\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	TMEM171 COL9A2 TMEM130 R3HDML SEZ6L2	5.80e-06	184	62	5	c3b848e1438a84b3fac8a4e40f3db478cc84d970
ToppCell	droplet-Kidney-nan-21m-Mesenchymal\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SSC5D LAMA4 SRPX GDF10 SVEP1	5.96e-06	185	62	5	33cc0e9d8b54cb7408b51235f2a70e044ebae04d
ToppCell	droplet-Lung-immune-endo-depleted-3m-Epithelial-lung_neuroendocrine_cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TMEM171 COL9A2 TMEM130 R3HDML SEZ6L2	5.96e-06	185	62	5	30263c558ee331e0879abcf8b4c2427ff05f9fe7
ToppCell	Adult-Mesenchymal-matrix_fibroblast_2_cell-D231\|Adult / Lineage, Cell type, age group and donor	CACNA1C SSC5D IGFBP5 LAMA4 SVEP1	5.96e-06	185	62	5	fb6bd7e849ecf4ed9cd9c4e2a946a2d12d62f804
ToppCell	droplet-Kidney-nan-21m-Mesenchymal-Stroma____fibroblast\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SSC5D LAMA4 SRPX GDF10 SVEP1	5.96e-06	185	62	5	9954fc85b183c1cc45c3c24e3dadc7984ee6f649
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2-Inh_L1-3_VIP_ZNF322P1\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	PXDN THSD7A IGFBP5 GDF10 SVEP1	5.96e-06	185	62	5	0b5a0df58ae2ad8261f40f152775747af4f3937a
ToppCell	droplet-Lung-immune-endo-depleted-3m-Epithelial-Neuroendocrine\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TMEM171 COL9A2 TMEM130 R3HDML SEZ6L2	5.96e-06	185	62	5	1b000ca11970db8f347eb97ff44605d562aea70a
ToppCell	356C-Endothelial_cells-Endothelial-E-\|356C / Donor, Lineage, Cell class and subclass (all cells)	VWF PXDN LAMA4 SRPX TAF1L	6.12e-06	186	62	5	2e024097ee361eeb1d855a4edb8ac8cdad35da06
ToppCell	356C-Endothelial_cells-Endothelial-E\|356C / Donor, Lineage, Cell class and subclass (all cells)	VWF PXDN LAMA4 SRPX TAF1L	6.12e-06	186	62	5	c3449e54454009973818fc1101933c6f0168258c
ToppCell	Adult-Mesenchymal-matrix_fibroblast_1_cell-D175\|Adult / Lineage, Cell type, age group and donor	ADAMTS12 CACNA1C ASXL3 LAMA4 SVEP1	6.28e-06	187	62	5	e15d2967aac248da3517bc2c7d1beaa1d5a0aa7f
ToppCell	Control-Fibroblasts-Other_FB\|Control / group, cell type (main and fine annotations)	ADAMTS12 CACNA1C SSC5D LAMA4 SVEP1	6.28e-06	187	62	5	bd3739c4a52aa1ba5deffd778e113a9800f7e158
ToppCell	droplet-Kidney-nan-3m-Mesenchymal-fibroblast\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ADAMTS12 SSC5D SRPX GDF10 SVEP1	6.78e-06	190	62	5	f61e21d53f2f7804ac6e40ab6c7f69838aa94d6a
ToppCell	droplet-Kidney-nan-3m-Mesenchymal\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ADAMTS12 SSC5D SRPX GDF10 SVEP1	6.78e-06	190	62	5	2abeb013bb83c578e67dcb985ba44ca63134950b
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ADAMTS12 CACNA1C LAMA4 GDF10 SVEP1	6.96e-06	191	62	5	b13229bb7f3713a392271aaf5dbae3edd1b9fe5a
ToppCell	facs-Heart-LV-3m-Mesenchymal\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SSC5D THSD7A KCP LAMA4 SVEP1	6.96e-06	191	62	5	b7a57691a4742070cee640e285c1f4d0da95baf1
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ADAMTS12 SSC5D IGFBP5 NR4A3 SVEP1	6.96e-06	191	62	5	1caf726bd07fdca389e678fc16304a6ef1790423
ToppCell	droplet-Lung-1m-Mesenchymal-fibroblast\|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	BMP3 LAMA4 SRPX GDF10 SVEP1	6.96e-06	191	62	5	ce80f65bd24b1c4d2152bf45248449e7a1a97e56
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2-Inh_L1-3_VIP_GGH\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	PXDN THSD7A IGFBP5 SEZ6L2 SVEP1	6.96e-06	191	62	5	06760c3bb40e4f66879a5f5e09c9abfce4ebbba3
ToppCell	ASK454-Mesenchymal\|ASK454 / Donor, Lineage and Cell class of Lung cells from Dropseq	SSC5D TMEM130 IGFBP5 LAMA4 SVEP1	6.96e-06	191	62	5	e30ae7a12439f8a79820b13f03e822c1223fd0cb
ToppCell	PCW_07-8.5-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro1_(4)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	ADAMTS12 CACNA1C IGFBP5 LAMA4 GDF10	6.96e-06	191	62	5	fa380a8752de158974b2ae5e741573439719cc0d
ToppCell	ASK454-Mesenchymal-Fibroblast\|ASK454 / Donor, Lineage and Cell class of Lung cells from Dropseq	SSC5D TMEM130 IGFBP5 LAMA4 SVEP1	6.96e-06	191	62	5	1726add3f392a061536b7aff72ba84303f4a0b1f
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ADAMTS12 SSC5D IGFBP5 NR4A3 SVEP1	6.96e-06	191	62	5	3d60c46bced2984c27a1fcf2910bc38b31fb0148
ToppCell	droplet-Kidney-nan-3m-Mesenchymal-Stroma____fibroblast\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ADAMTS12 SSC5D SRPX GDF10 SVEP1	6.96e-06	191	62	5	d1205aab0937f2becfcd239610e9b78fb8a0c886
ToppCell	COVID-19-Heart-Fib_+_EC_+_Pericyte\|Heart / Disease (COVID-19 only), tissue and cell type	VWF ARSJ PXDN SRPX SVEP1	7.14e-06	192	62	5	60b1312e84f6d6448365a952469c506c00b5fe93
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ADAMTS12 CACNA1C LAMA4 GDF10 SVEP1	7.14e-06	192	62	5	3d0cb19f037f604253d7d728689aeaa94251e92b
ToppCell	COPD-Stromal-Myofibroblast\|Stromal / Disease state, Lineage and Cell class	ADAMTS12 LAMA4 GDF10 ZYX SVEP1	7.14e-06	192	62	5	62904f94dfce430456f05066522cbf9bd29f4d7e
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro1_(4)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	ADAMTS12 CACNA1C PTPRK LAMA4 ZYX	7.32e-06	193	62	5	9f69edc97b868d23998abc98928a2e89a885ef8a
ToppCell	PCW_07-8.5-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_adventitial_fibro_(9)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	ADAMTS12 THSD7A LAMA4 GDF10 SVEP1	7.50e-06	194	62	5	5f5f0cdeacd5e1b28717d78dabdb9eb95f661e36
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ADAMTS12 PXDN IGFBP5 LAMA4 SVEP1	7.50e-06	194	62	5	240d122dcb9dd1ab2867503ad85869853adcacae
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ADAMTS12 PXDN IGFBP5 LAMA4 SVEP1	7.50e-06	194	62	5	ae7df037592f1c20c9d32be15fe6fc3c562ebeb1
ToppCell	Control-Stromal-Myofibroblast\|World / Disease state, Lineage and Cell class	ADAMTS12 CACNA1C LAMA4 GDF10 SVEP1	7.50e-06	194	62	5	3c2266772c5b56e8e02a461e5193e29588028ee9
ToppCell	LPS-antiTNF-Stromal_mesenchymal\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ADAMTS12 CACNA1C LAMA4 GDF10 SVEP1	7.50e-06	194	62	5	6e13549f697f7478b34fe71f7dd9d63c5d3db22e
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ADAMTS12 CACNA1C ASXL3 LAMA4 SVEP1	7.50e-06	194	62	5	89b706af2b25991fc2707eb24f49ba6ff3ae01f7
ToppCell	TCGA-Blood_and_Bone_Marrow-Primary_Tumor-Diffuse_large_B-cell_lymphoma-DLBCL-1\|TCGA-Blood_and_Bone_Marrow / Sample_Type by Project: Shred V9	ADAMTS12 TRAFD1 ARSJ PTPRK LAMA4	7.50e-06	194	62	5	eaeeb84576270cc3fc59002ba33bff9639bb0b02
ToppCell	PCW_07-8.5-Mesenchymal-Mesenchymal_fibroblastic-mes_immature1_(0)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	ADAMTS12 THSD7A LAMA4 GDF10 SVEP1	7.50e-06	194	62	5	a3e5a15cf6c1361207f661ee15eb634f77daf1cb
ToppCell	Control-Stromal-Myofibroblast\|Control / Disease state, Lineage and Cell class	ADAMTS12 CACNA1C LAMA4 GDF10 SVEP1	7.69e-06	195	62	5	ffcf76cd72e43d8cf1058a49c76e0956065038bc
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature3_(17)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	ADAMTS12 THSD7A LAMA4 GDF10 SVEP1	7.69e-06	195	62	5	1cdf5f296029ae424d9dba42e86a6d111e4896e6
ToppCell	Control-Stromal-Fibroblast\|Control / Disease state, Lineage and Cell class	PXDN IGFBP5 LAMA4 SRPX SVEP1	7.89e-06	196	62	5	7ca94477498a84cafcdd9933ee92a6cbde76c70e
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	ADAMTS12 THSD7A LAMA4 GDF10 SVEP1	7.89e-06	196	62	5	1450cb69c5bf469e97c03bf1890f6f7c54165b8a
ToppCell	Tracheal-NucSeq-Stromal-Fibroblastic-Fibro_myofibroblast\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	CACNA1C LAMA4 SRPX GDF10 SVEP1	8.08e-06	197	62	5	0dd71e399f253787fa546a7e90c5373180b89ffd
ToppCell	COPD-Stromal-Myofibroblast\|World / Disease state, Lineage and Cell class	ADAMTS12 CACNA1C LAMA4 GDF10 SVEP1	8.08e-06	197	62	5	d51f484b4e01ac64233950d0b97fa88825ea1dbb
ToppCell	10x_3'_v3-tissue-resident_(10x_3'_v3)-mesenchymal-mesenchymal-mesenchymal_stem_cell\|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	PXDN IGFBP5 LAMA4 SRPX SVEP1	8.08e-06	197	62	5	3bb92dd8a94e2be3b7fe51c9a21b241215477ac7
ToppCell	PCW_13-14-Mesenchymal\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	ADAMTS12 CACNA1C LAMA4 GDF10 SVEP1	8.08e-06	197	62	5	73a2085d2682d636726a5432d572ae2a3fbe1c3f
ToppCell	10x_3'_v3-tissue-resident_(10x_3'_v3)-mesenchymal\|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	PXDN IGFBP5 LAMA4 SRPX SVEP1	8.08e-06	197	62	5	17344464fdcc5ba0c03959696b97c195f11e644c
ToppCell	COPD-Stromal\|COPD / Disease state, Lineage and Cell class	CACNA1C IGFBP5 LAMA4 GDF10 SVEP1	8.08e-06	197	62	5	d5390d86acaa8c39f1da893e8d2271f9ed2951d7
ToppCell	10x_3'_v3-tissue-resident_(10x_3'_v3)-mesenchymal-mesenchymal\|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	PXDN IGFBP5 LAMA4 SRPX SVEP1	8.08e-06	197	62	5	5b8d0d7116b20d8e27541e88ec80c9f1f477e384
ToppCell	LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts-Diff_MatrixFB\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	ADAMTS12 SRPX GDF10 ZYX SVEP1	8.28e-06	198	62	5	0a4b19c3d5e65ecd24fc2ce80ac5276c813282c7
ToppCell	background-Hepatic_Stellate_cells\|World / Sample and Cell Type and Tumor Cluster (all cells)	SSC5D IGFBP5 ADAMTS13 SRPX SVEP1	8.28e-06	198	62	5	79f32f965aed6a10c5cb803173e3db7b32e07a91
ToppCell	(5)_Fibroblasts-(5)_Fibroblast-B_(Myofibroblast)\|(5)_Fibroblasts / Lung cell shreds - cell class (v4) and cell subclass (v4)	ADAMTS12 SSC5D IGFBP5 SPRR3 SEZ6L2	8.28e-06	198	62	5	196257c4420ac801ed9fbb444f11718adb7560ae
ToppCell	background-Hepatic_Stellate_cells\|background / Sample and Cell Type and Tumor Cluster (all cells)	CACNA1C SSC5D IGFBP5 ADAMTS13 SVEP1	8.28e-06	198	62	5	bd11b0e9e80449aab979a02c1023e0638c431c7c
ToppCell	5'-Parenchyma_lung-Endothelial-Blood_vessel_EC-capillary_endothelial_cell-EC_general_capillary-EC_general_capillary_L.2.0.2.2\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	VWF PXDN ADAM15 LAMA4 SRPX	8.28e-06	198	62	5	0c8ec287500c58938ecc0dbbbc5f6c7a48733fc6
ToppCell	cellseq-Mesenchymal-Fibroblastic-Fibroblastic_2-AF1\|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	ADAMTS12 CACNA1C LAMA4 GDF10 SVEP1	8.28e-06	198	62	5	f1374f7a50244d59c766ac41f44c08c9117407d2
ToppCell	proximal-mesenchymal-Alveolar_Fibroblast\|proximal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	ADAMTS12 LAMA4 GDF10 ZYX SVEP1	8.49e-06	199	62	5	7f4840ae6a888380feca722543e5e52783f3e35d
ToppCell	Fetal_29-31_weeks\|World / Lineage, Cell type, age group and donor	ADAMTS12 CACNA1C PXDN ASXL3 LAMA4	8.49e-06	199	62	5	5b9d355795dd03a22f0961dfd143425c367a4654
ToppCell	proximal-3-mesenchymal-Alveolar_Fibroblast\|3 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	ADAMTS12 LAMA4 GDF10 ZYX SVEP1	8.49e-06	199	62	5	301d02bbb37e6f1d24b6e865bc3fe3e91260eb30
ToppCell	3'-GW_trimst-1-SmallIntestine-Mesenchymal\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	PXDN IGFBP5 LAMA4 ZYX SVEP1	8.49e-06	199	62	5	36c1deac7ef0f9ebde6b2f7a63f7daa03d8c139a
Drug	UAMC00132	DPP9 DPP8	7.30e-06	2	62	2	ctd:C524159
Drug	Mephenytoin [50-12-4]; Up 200; 18.4uM; HL60; HT_HG-U133A	ADAMTS12 MYT1 CACNA1I TACC2 MUC2 SH3D21	1.55e-05	196	62	6	6158_UP
Drug	Deltaline [6836-11-9]; Up 200; 7.8uM; HL60; HT_HG-U133A	TRAFD1 THSD7A SRPX SH3D21 SVEP1 MASP2	1.64e-05	198	62	6	2171_UP
Drug	Dizocilpine maleate [77086-22-7]; Up 200; 11.8uM; MCF7; HT_HG-U133A	ADAMTS12 IGFBP5 TAF1 MUC5AC SH3D21 SVEP1	1.69e-05	199	62	6	2232_UP
Drug	SureCN3749646	DPP9 DPP8	2.18e-05	3	62	2	CID011530920
Drug	Mfpa	TAF1 TAF1L	2.18e-05	3	62	2	CID003035615
Drug	SureCN3745540	DPP9 DPP8	2.18e-05	3	62	2	CID011974437
Drug	SureCN3749947	DPP9 DPP8	2.18e-05	3	62	2	CID011974435
Drug	ABT-279	DPP9 DPP8	2.18e-05	3	62	2	CID016049769
Drug	Cyanopyrrolidine 38	DPP9 DPP8	2.18e-05	3	62	2	CID010932707
Drug	Cyanopyrrolidine 39	DPP9 DPP8	2.18e-05	3	62	2	CID011117606
Drug	SureCN3748611	DPP9 DPP8	2.18e-05	3	62	2	CID011974325
Drug	Diprolyl-alanine	DPP9 DPP8	2.18e-05	3	62	2	CID000193559
Drug	glycylproline 4-nitroanilide	DPP9 DPP8	4.36e-05	4	62	2	ctd:C042892
Drug	cypermethrin	SP100 DPP9 DPP8	6.00e-05	28	62	3	CID000002912
Drug	Deprolorphin	PTPN11 DPP9 DPP8	6.00e-05	28	62	3	CID000122318
Drug	prodipine	DPP9 DPP8	7.26e-05	5	62	2	CID000065775
Drug	arginyl(PMC)-pyrrolidine-2-nitrile	DPP9 DPP8	7.26e-05	5	62	2	CID000487437
Drug	alanylproline-4-nitroanilide	DPP9 DPP8	7.26e-05	5	62	2	ctd:C083013
Drug	Protease Inhibitors	DPP9 DPP8	1.09e-04	6	62	2	ctd:D011480
Drug	cathepsin C substrate	DPP9 DPP8	1.09e-04	6	62	2	CID003508173
Drug	NVP-DPP728	DPP9 DPP8	1.09e-04	6	62	2	CID009796290
Drug	In2-7	COL9A2 VWF	1.09e-04	6	62	2	CID002816385
Drug	MK-251	DPP9 DPP8	1.09e-04	6	62	2	CID000176160
Drug	II 19	DPP9 DPP8	1.09e-04	6	62	2	CID000040321
Drug	Mifepristone	VWF PXDN IGFBP5 PTPRK ADAM15 HRAS SRPX SVEP1	1.23e-04	553	62	8	ctd:D015735
Drug	Epostatin	DPP9 DPP8	1.52e-04	7	62	2	CID006449105
Drug	o-Py	DPP9 DPP8	1.52e-04	7	62	2	CID009942336
Drug	PF-00875133-00 [351322-64-0]; Up 200; 10uM; MCF7; HT_HG-U133A	ADAMTS12 IGFBP5 TAF1 TNFRSF21 SH3D21	1.77e-04	192	62	5	5967_UP
Drug	Promethazine hydrochloride [58-33-3]; Up 200; 12.4uM; HL60; HT_HG-U133A	THSD7A CACNA1I ADAMTS13 SH3D21 CASZ1	1.86e-04	194	62	5	3100_UP
Drug	Folic acid [59-30-3]; Up 200; 9uM; MCF7; HT_HG-U133A	ADAMTS12 TRAFD1 CACNA1I TAF1 TNFRSF21	1.95e-04	196	62	5	2783_UP
Drug	PHA-00745360 [351320-33-7]; Down 200; 10uM; MCF7; HT_HG-U133A	IGFBP5 CACNA1I SRPX SVEP1 MASP2	1.95e-04	196	62	5	4381_DN
Drug	Ampyrone [83-07-8]; Up 200; 19.6uM; MCF7; HT_HG-U133A	ADAMTS12 MYT1 LAMA4 TNFRSF21 SVEP1	2.00e-04	197	62	5	2249_UP
Drug	CID6451162	DPP9 DPP8	2.02e-04	8	62	2	CID006451162
Drug	4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-anthracenyl)benzoic acid	MUC2 MUC5AC	2.02e-04	8	62	2	ctd:C064545
Drug	P32/98	DPP9 DPP8	2.02e-04	8	62	2	CID006918464
Drug	imidazolelactate	DPP9 DPP8	2.02e-04	8	62	2	CID000000793
Drug	novobiocin sodium, USP; Up 200; 100uM; MCF7; HG-U133A	TRAFD1 SAC3D1 CACNA1I TNFRSF21 MASP2	2.05e-04	198	62	5	437_UP
Drug	(S)-(-)-Atenolol [93379-54-5]; Up 200; 15uM; HL60; HT_HG-U133A	PTPRK NR4A3 CACNA1I ADAMTS13 CASZ1	2.05e-04	198	62	5	3067_UP
Drug	Tetramisole hydrochloride [16595-80-5]; Up 200; 16.6uM; MCF7; HT_HG-U133A	SP100 LAMA4 TAF1 MUC2 SVEP1	2.05e-04	198	62	5	2849_UP
Drug	Avermectin B1 [71751-41-2]; Up 200; 4.8uM; HL60; HT_HG-U133A	IGFBP5 LAMA4 CACNA1I MUC2 TNFRSF21	2.05e-04	198	62	5	2519_UP
Drug	Lobeline alpha (-) hydrochoride [134-63-4]; Up 200; 10.6uM; MCF7; HT_HG-U133A	IGFBP5 ADAMTS13 MUC5AC SH3D21 MASP2	2.10e-04	199	62	5	2763_UP
Drug	Leucomisine [17946-87-1]; Up 200; 16.2uM; MCF7; HT_HG-U133A	SP100 IGFBP5 LAMA4 CACNA1I MUC5AC	2.10e-04	199	62	5	3546_UP
Drug	Pargyline hydrochloride [306-07-0]; Up 200; 20.4uM; MCF7; HT_HG-U133A	SP100 IGFBP5 ADAMTS13 SRPX TNFRSF21	2.10e-04	199	62	5	7016_UP
Drug	Citalopram hydrobromide [59729-32-7]; Down 200; 1uM; PC3; HT_HG-U133A	SP100 COL9A2 IGFBP5 BAHD1 CASZ1	2.10e-04	199	62	5	4555_DN
Drug	ICI182,780; Down 200; 1uM; PC3; HT_HG-U133A	SP100 ADAM15 CACNA1I TAF1 MASP2	2.14e-04	200	62	5	5931_DN
Drug	Cinnarizine	CACNA1C CACNA1I	2.59e-04	9	62	2	DB00568
Drug	NSC-334212	DPP9 DPP8	2.59e-04	9	62	2	CID000333414
Drug	Gly-pro-na	DPP9 DPP8	2.59e-04	9	62	2	CID000194319
Drug	isoindoline	DPP9 DPP8	2.59e-04	9	62	2	CID000422477
Drug	Appna	DPP9 DPP8	2.59e-04	9	62	2	CID006453929
Drug	Phe-pro-ala	DPP9 DPP8	2.59e-04	9	62	2	CID000133668
Drug	SureCN475872	DPP9 DPP8	2.59e-04	9	62	2	CID011163584
Disease	extrapulmonary tuberculosis	CACNA1C THSD7A ADAM15	1.92e-06	12	62	3	MONDO_0000368
Disease	cystitis (is_marker_for)	MUC2 MUC5AC	4.34e-06	2	62	2	DOID:1679 (is_marker_for)
Disease	sputum mucin-5B amount	MUC2 MUC5AC	1.30e-05	3	62	2	OBA_2050332
Disease	Sushi, von Willebrand factor type A, EGF and pentraxin domain-containing protein 1 measurement	ADAM15 SVEP1	2.60e-05	4	62	2	EFO_0803113
Disease	mucinous adenocarcinoma (is_marker_for)	MUC2 MUC5AC	4.33e-05	5	62	2	DOID:3030 (is_marker_for)
Disease	Neuroblastoma	PTPN11 DOCK8 HRAS	1.34e-04	47	62	3	C0027819
Disease	bringing up phlegm, sputum or mucus on most days, self-reported	MUC2 MUC5AC	1.55e-04	9	62	2	EFO_0009824
Disease	cystatin C measurement	GRAMD2A PTPN11 TRAFD1 KCP ATF6B MASP2	1.99e-04	402	62	6	EFO_0004617
Disease	von Willebrand factor measurement	TMEM171 VWF ADAMTS13	2.26e-04	56	62	3	EFO_0004629
Disease	Turner Syndrome, Male	PTPN11 HRAS	2.36e-04	11	62	2	C0041409
Disease	Female Pseudo-Turner Syndrome	PTPN11 HRAS	2.36e-04	11	62	2	C1527404
Disease	Noonan Syndrome 1	PTPN11 HRAS	2.36e-04	11	62	2	C4551602
Disease	eosinophil count	PTPN11 TRAFD1 PXDN MYT1 HRAS KCP MUC2 MUC5AC ATF6B SF3B5 SVEP1	2.45e-04	1488	62	11	EFO_0004842
Disease	systemic lupus erythematosus	TRAFD1 RAPH1 ADAM15 MYT1 KCP NR4A3 IQCN SEZ6L2	2.59e-04	799	62	8	MONDO_0007915
Disease	age-related macular degeneration, COVID-19	DPP9 TACC2 CFHR4	4.19e-04	69	62	3	EFO_0001365, MONDO_0100096
Disease	RASopathy	PTPN11 HRAS	4.48e-04	15	62	2	cv:C5555857
Disease	T-Cell Lymphoma	ASXL3 HRAS	5.11e-04	16	62	2	C0079772
Disease	idiopathic scoliosis (implicated_via_orthology)	PTPN11 SSPOP	5.11e-04	16	62	2	DOID:0060250 (implicated_via_orthology)
Disease	alcohol dependence	CACNA1C ASXL3 MUC2 MUC5AC	6.03e-04	183	62	4	MONDO_0007079
Disease	Agents acting on the renin-angiotensin system use measurement	CACNA1C PTPN11 MYT1 CASZ1 SVEP1	6.97e-04	335	62	5	EFO_0009931
Disease	Noonan-Like Syndrome With Loose Anagen Hair	PTPN11 HRAS	7.26e-04	19	62	2	C3501846
Disease	Costello syndrome (disorder)	PTPN11 HRAS	7.26e-04	19	62	2	C0587248
Disease	Noonan syndrome-like disorder with loose anagen hair	PTPN11 HRAS	7.26e-04	19	62	2	C1843181
Disease	factor VIII measurement, Ischemic stroke	TMEM171 VWF	7.26e-04	19	62	2	EFO_0004630, HP_0002140
Disease	leukemia (implicated_via_orthology)	PTPN11 HRAS	7.26e-04	19	62	2	DOID:1240 (implicated_via_orthology)
Disease	Cardio-facio-cutaneous syndrome	PTPN11 HRAS	7.26e-04	19	62	2	C1275081
Disease	Varicose veins	DOCK8 ADAM15 SRPX CASZ1	7.36e-04	193	62	4	HP_0002619
Disease	systemic scleroderma	PXDN KCP CR2	7.72e-04	85	62	3	EFO_0000717
Disease	glaucoma (is_marker_for)	PTPN11 MUC5AC	8.05e-04	20	62	2	DOID:1686 (is_marker_for)
Disease	coagulation factor measurement	VWF CFHR4	8.05e-04	20	62	2	EFO_0004634
Disease	LEOPARD Syndrome	PTPN11 HRAS	9.77e-04	22	62	2	C0175704
Disease	Neurodevelopmental Disorders	PTPN11 DOCK8 ASXL3	1.00e-03	93	62	3	C1535926
Disease	Noonan Syndrome	PTPN11 HRAS	1.16e-03	24	62	2	C0028326
Disease	factor VIII measurement, von Willebrand factor measurement	TMEM171 VWF	1.47e-03	27	62	2	EFO_0004629, EFO_0004630
Disease	Ischemic stroke, von Willebrand factor measurement	TMEM171 VWF	1.82e-03	30	62	2	EFO_0004629, HP_0002140
Disease	von Willebrand factor measurement, coronary artery disease	TMEM171 VWF TRAFD1	1.99e-03	118	62	3	EFO_0001645, EFO_0004629
Disease	coffee consumption	PTPN11 TRAFD1	2.07e-03	32	62	2	EFO_0004330

Protein segments in the cluster

Peptide	Gene	Start	Entry
GIPEPCCVPEKMSSL	BMP3	431	P12645
MEPASCCAERPKPGP	BRICD5	1	Q6PL45
CTDPPAGKPAMAPKR	CASZ1	11	Q86V15
PCPGPAPAKTCIMEA	ADAM15	366	Q13444
PASPEPGFCATLCPM	ASXL3	411	Q9C0F0
PGFCATLCPMVEIPP	ASXL3	416	Q9C0F0
IPPPLSMSCNPEPCE	ADAMTS12	1411	P58397
EKLPAPEPCVGMSCP	ADAMTS13	851	Q76LX8
LNPPDESGPGCMSCK	HRAS	171	P01112
PGSAMAQLKPAPCAP	RAPH1	721	Q70E73
PCPAACEVQGMLVPP	IQCN	821	Q9H0B3
EKMQPCCKAPDIPTP	KIAA0100	626	Q14667
TALPCPPCQVPIPME	NFXL1	626	Q6ZNB6
PPPSPQACVCPGKML	ARSJ	11	Q5FYB0
PGIPEPCCVPDKMNS	GDF10	436	P55107
VECEPPPMPTCSNGL	MUC2	4446	Q02817
DEKALSMCPPSPLGC	IGFBP5	31	P24593
SMCPPSPLGCELVKE	IGFBP5	36	P24593
KMQCVATCPTPPLPP	MUC5AC	1221	P98088
PPCTPTPPCAEMRED	PTPN11	561	Q06124
LACMPGKKCAPESEP	CACNA1C	1471	Q13936
TKMPVCEEIFCPSPP	CR2	266	P20023
CCLTPEMLPVKPFPE	DOCK8	521	Q8NF50
PICLGTAPGCLMPAV	ERVK-24	51	P61566
GPRMDPKICPADPAF	DPP9	186	Q86TI2
DSSGDPKLCPIPMTP	CACNA1I	896	Q9P0X4
CPNIRMDPKLCPADP	DPP8	211	Q6V1X1
DFLCPTNCPPGMKGP	COL9A2	171	Q14055
CPMLPEGKLSPVAAP	BAHD1	396	Q8TBE0
EPPRCISMKPCEFPE	CFHR4	261	Q92496
RPMPACSIVDCGPPD	MASP2	356	O00187
VDSKDPTLGMSCPPP	METTL13	576	Q8N6R0
GPACPKKMPNCSPTA	GRAMD2A	271	Q8IUY3
ELPVGTCPDMCPAAE	SAC3D1	51	A6NKF1
ESPYKMGKPCSSCPP	R3HDML	216	Q9H3Y0
PGPPLITRTKCAEPM	PTPRK	376	Q15262
EPPTGMDCPTISCDK	LAMA4	261	Q16363
CIAPGPLLDPPMKAV	NR4A3	166	Q92570
PPQPPSSERCLGEMK	SH3D21	421	A4FU49
QPCAGPVPGMCPRDK	SSPOP	3081	A2VEC9
QPCPWPMIEKLPCAA	TNFRSF21	111	O75509
IGMCPTCKEPFPKSD	TRAFD1	36	O14545
MPLGSRVCKLPCPED	THSD7A	1151	Q9UPZ6
PSLMDQSKPCPVKPC	THSD7A	1326	Q9UPZ6
DCEDIDCKLMPPPPP	TAF1L	146	Q8IZX4
ADCEDIDCKLMPPPP	TAF1	146	P21675
VRCMALKCPPSPCPE	KCP	226	Q6ZWJ8
QCCNPPLSEEMLPPG	PHF12	81	Q96QT6
PPACQKIMTCADPGE	SEZ6L2	696	Q6UXD5
PASCVDMEPPRIKCP	SRPX	171	P78539
GPCVAPTPPVRVMAC	SSC5D	1471	A1L4H1
PMSIQCIPVRCGEPP	SVEP1	2136	Q4LDE5
PLMCVPLDCGKPPPI	SVEP1	2256	Q4LDE5
KMLQPCGPPADKPEE	SF3B5	71	Q9BWJ5
CTKVPEPGCTKVPEP	SPRR3	66	Q9UBC9
KVPEPGCTKVPEPGC	SPRR3	76	Q9UBC9
PMPGNSCPPEVDAKL	ATF6B	311	Q99941
CPMKPKKEASEVCPP	PIAS3	406	Q9Y6X2
KDLFEGRPPMEQPPC	TCEAL1	76	Q15170
PSEGCFCPPDKVMLE	VWF	2231	P04275
FCPPDKVMLEGSCVP	VWF	2236	P04275
GREMPCPLPCDEESP	SP100	261	P23497
KPLLPFATGPPTECM	PXDN	946	Q92626
MCGQKAPDLPPVPEE	TMEM52B	151	Q4KMG9
MPFAECPPEGCLASP	TACC2	111	O95359
SPVPLREPMKAPLCG	TACC2	201	O95359
PLPDCPMVLKVAGPA	TMEM171	51	Q8WVE6
CFAVPDPLMPDPSKQ	PRKRA	106	O75569
APRCSVCSEPIMPEP	ZYX	501	Q15942
PMSDKNPEPPSGVRC	TMEM130	381	Q8N3G9
EDPELMKCPVPGCVG	MYT1	886	Q01538